The area of anti-infectives represents an exciting
frontier for development of potential life-saving products. However, there are
a number of issues and trends that have a direct influence on this market and
manufacturers' ability to successfully operate in the market. The issues and
trends affecting this market include:
·
Drug Resistance
·
HIV Trends, Cost, and Access to Drug
Therapy
·
Other Immunocompromised Population Issues
·
Alliances and Partnerships
·
New Developments
·
Rx-to-OTC Switches
The information for this report was gathered using both
primary and secondary research including comprehensive research of secondary
sources such as company literature, databases, investment reports, and medical
and business journals focused on the anti-infective industry. Telephone
interviews and email correspondence were the primary method of gathering
information. For the purpose of this study Kalorama Information conducted
interviews with key industry officials, consultants, health care providers, and
government personnel.
These sources were
the primary basis in gathering information specifically relating to revenue and
market share data presented in this report. Specific interviews with pharmaceutical
company representatives included marketing directors, division managers, and
product representatives.
Request a Sample for or Inquire before buying the report@
Additional
Information
Gilead Leads Antiviral Therapy Sales: Kalorama
With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck. Led by growth in antivirals, the market for all anti-infectives reached $53 billion in 2011, according to this new report by Kalorama Information.
Atripla is the company's newest antiviral product, launched in July 2006, and it's the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or "cocktail" that under best conditions can reduce the presence of HIV RNA in the patient's plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product's sales to be $3.2 billion in 2011. Truvada, Viread, Hepsera are the company's other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership.
Gilead Leads Antiviral Therapy Sales: Kalorama
With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck. Led by growth in antivirals, the market for all anti-infectives reached $53 billion in 2011, according to this new report by Kalorama Information.
Atripla is the company's newest antiviral product, launched in July 2006, and it's the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or "cocktail" that under best conditions can reduce the presence of HIV RNA in the patient's plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product's sales to be $3.2 billion in 2011. Truvada, Viread, Hepsera are the company's other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership.
Major points
covered in Table of Contents of this report include:
Introduction
INTRODUCTION AND INDUSTRY TRENDS
ANTIFUNGAL DRUGS
ANTIBACTERIAL DRUGS
ANTIVIRAL DRUGS
MARKET SUMMARY
CORPORATE PROFILES
COMPANY DIRECTORY
Explore Comprehensive list of more than Tables &
Figures available in the report @ http://www.reportsnreports.com/reports/145414-world-market-for-anti-infectives-antifungals-antibacterials-and-antivirals-.html
Report Details:
Published: February 2012
Published: February 2012
No. of Pages: 220
Price: Single User License – US $ 3800
Price: Single User License – US $ 3800
No comments:
Post a Comment